Sign in

You're signed outSign in or to get full access.

Ygal Nochomovitz

Director and SMid Cap Biotech Analyst at Citi

Ygal Nochomovitz is a Director and SMid Cap Biotech Analyst at Citi, specializing in in-depth equity research across the biotechnology sector with a focus on companies in ophthalmology, oncology, rare diseases, nephrology, and infectious disease spaces. He covers a large portfolio of biotech stocks including names such as APLS, LXRX, and MRTX, and has achieved an average returns rate of 3.1% per transaction with a 38% success rate, highlighted by a top-performing call on RETA stock with a 675.5% return. Nochomovitz joined Citi in 2015 after senior analyst and vice president roles at Oppenheimer, Morgan Stanley, Rodman & Renshaw, and SIG Susquehanna, and he began his Wall Street career in 2008 after postdoctoral work at Rockefeller University. He holds a PhD in Biophysics from the University of California, San Francisco, a BS in Biochemistry from Brown University, and maintains professional credentials including required FINRA registrations for equity research analysts.

Ygal Nochomovitz's questions to Ultragenyx Pharmaceutical (RARE) leadership

Question · Q4 2025

Yigal Dov Nochomovitz requested more details on the DTX-301 (OTC) study, its prominence in success expectations, and what would be needed for the study to hit. He also asked if the UX111 IRL requests, which would typically occur during an inspection, mean the inspection would be limited or different.

Answer

Emil Kakkis, Chief Executive Officer and President, explained that the DTX-301 Phase III trial (37 patients) is looking at change in ammonia between treated and control groups as the primary endpoint, with a secondary focus on patients getting off standard of care. He noted it's an important program but not their top priority. Regarding the UX111 IRL, he expects the FDA will still inspect, but providing comprehensive documentation upfront aims to give them greater confidence that all requests have been addressed.

Ask follow-up questions

Fintool

Fintool can predict Ultragenyx Pharmaceutical logo RARE's earnings beat/miss a week before the call

Ygal Nochomovitz's questions to NEUROCRINE BIOSCIENCES (NBIX) leadership

Question · Q3 2025

Ygal Nochomovitz asked about Neurocrine Biosciences' capital management, specifically the continuation and pace of the buyback program related to the new $500 million allocation, considering the increased SG&A for sales force expansion.

Answer

Matt Abernethy, Chief Financial Officer, highlighted the company's $2.1 billion cash balance and profitability. He stated that capital allocation prioritizes top-line growth and R&D investment (targeting 35%), with a bias towards business development and internal initiatives, while maintaining flexibility for share buybacks.

Ask follow-up questions

Fintool

Fintool can predict NEUROCRINE BIOSCIENCES logo NBIX's earnings beat/miss a week before the call

News for Covered Companies

Ultragenyx Crashes 44% After Setrusumab Fails Two Phase 3 Trials

Ultragenyx Crashes 44% After Setrusumab Fails Two Phase 3 Trials

RAREDec 29, 2025